Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Adherex Technologies, Inc. |
---|---|
Information provided by: | Adherex Technologies, Inc. |
ClinicalTrials.gov Identifier: | NCT00264433 |
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.
Condition | Intervention | Phase |
---|---|---|
Neoplasms |
Drug: ADH -1 (Exherin™) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically proven advanced and/or metastatic solid tumor of one of the following histologies:
Exclusion Criteria:
History of:
United States, Florida | |
Florida Cancer Specialist | |
Fort Myers, Florida, United States, 33908 | |
United States, North Carolina | |
Lineberger Comprensive Cancer Center | |
Chapel Hill, North Carolina, United States, 27599 | |
Duke Comprehensive Cancer Centre | |
Durham, North Carolina, United States, 27703 | |
United States, Tennessee | |
Sarah Cannon Research Institute | |
Nashville, Tennessee, United States, 37203 | |
Chattanooga Oncology and Hematology Associates | |
Chattanooga, Tennessee, United States, 37404 | |
Canada, Alberta | |
Cross Cancer Institute | |
Edmonton, Alberta, Canada | |
Canada, British Columbia | |
BC Cancer Agency - Vancouver Centre | |
Vancouver, British Columbia, Canada | |
Canada, Nova Scotia | |
Centre for Clinical Research | |
Halifax, Nova Scotia, Canada | |
Canada, Ontario | |
The Ottawa Hospital Regional Cancer Center (TOHRCC) | |
Ottawa, Ontario, Canada, K1H 1C4 | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 | |
Canada, Quebec | |
McGill University Jewish General Hospital | |
Montreal, Quebec, Canada, H3T 1E2 |
Study ID Numbers: | Adherex Protocol # AHX-01-201 |
Study First Received: | December 12, 2005 |
Last Updated: | August 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00264433 |
Health Authority: | United States: Food and Drug Administration |
Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents Cadherins; Non-Small-Cell Lung Carcinoma; Esophageal Cancer; Gastric Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Adrenocortical Carcinoma |
Non-small cell lung cancer Esophageal disorder Carcinoma, Hepatocellular Adrenocortical carcinoma Esophageal Neoplasms Adrenocortical Carcinoma Stomach cancer Renal cancer Kidney cancer |
Recurrence Carcinoma Lung Neoplasms Stomach Neoplasms Carcinoma, Renal Cell Esophageal Diseases Carcinoma, Non-Small-Cell Lung Esophageal neoplasm Hepatocellular carcinoma |
Neoplasms |